5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

NCT00433927 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

568

Enrollment

OTHER

Sponsor class

Conditions

Neoplasm Metastasis
Colorectal Cancer

Interventions

DRUG: 5-FU
DRUG: folinic acid
DRUG: irinotecan
DRUG: cetuximab
DRUG: bevacizumab

Sponsor

PD Dr. med. Volker Heinemann

Collaborators

[object Object]